Pharmaceutical company · SNY

Sanofi
clinical trial
pipeline

Registry checked

Published

Immunology & Inflammation is the largest mapped primary therapeutic group, with 25 of 184 active trials. This ranking covers mapped groups only. Dupilumab is linked to 19 distinct active studies, with 1 Phase 2, 3 Phase 3, 5 Phase 4, 10 without a recorded phase. Rilzabrutinib is linked to 9 distinct active studies, with 2 Phase 1, 2 Phase 2, 5 Phase 3.

47 active trials lack a mapped primary therapeutic group. The categories and accepted programme links are partial enrichment, so individual study records provide additional context.

Active trial mix

Lead-sponsor scope

184active trials
as lead sponsor
  • Phase 110
  • Phase 256
  • Phase 356
  • Phase 414
  • Phase not recorded48

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

02 Oct 2026 – 31 Oct 2026 · UTC

Recorded changes

5131 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 03

Select an example to see what changed

01First observed trial
Not previously observed by ComplyRxFirst observed by ComplyRx

A Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis

NCT07905547 · ClinicalTrials.gov
Recorded by ComplyRx
30 Oct 2026
Registry last updated
29 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-021110031
2026-10-032100142
2026-10-040000000
2026-10-050000000
2026-10-060000000
2026-10-070000000
2026-10-081000011
2026-10-090010011
2026-10-100000663
2026-10-110000000
2026-10-120000000
2026-10-131010021
2026-10-140100122
2026-10-151110253
2026-10-161000011
2026-10-170000221
2026-10-180000000
2026-10-191000011
2026-10-200000000
2026-10-213210065
2026-10-220000111
2026-10-231110031
2026-10-241100133
2026-10-250000000
2026-10-260000000
2026-10-271200032
2026-10-280000000
2026-10-292220062
2026-10-300001011
2026-10-310000000
Type totals161281145131 distinct

02 / Drugs & programmes

Explore the pipeline

6 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

Dupilumab

Dupixent

19
Active trials
8
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 21
  • Phase 33
  • Phase 45
  • Phase not recorded10
Studied condition
Asthma · Atopic Dermatitis · Chronic Obstructive Pulmonary Disease
Next primary completion
02 June 2027 · estimated
Open drug

Rilzabrutinib

wayrilz

9
Active trials
6
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 12
  • Phase 22
  • Phase 35
  • Phase 40
  • Phase not recorded0
Studied condition
Autoimmune Haemolytic Anaemia · Graves' Disease · Healthy Volunteer
Next primary completion
30 November 2026 · estimated
Open drug

Isatuximab

sarclisa · sarclisaescena

7
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 24
  • Phase 33
  • Phase 40
  • Phase not recorded0
Studied condition
Plasma Cell Myeloma · Plasma Cell Myeloma Recurrent · Plasma Cell Myeloma Refractory
Next primary completion
01 April 2027 · estimated
Open drug

Belumosudil

rezurock

6
Active trials
2
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 11
  • Phase 21
  • Phase 33
  • Phase 41
  • Phase not recorded0
Studied condition
Chronic Graft Versus Host Disease · Lung Transplant Rejection
Next primary completion
Not reported
Open drug

Frexalimab

Canonical investigational asset

6
Active trials
3
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 22
  • Phase 34
  • Phase 40
  • Phase not recorded0
Studied condition
Focal Segmental Glomerulosclerosis · Glomerulonephritis Minimal Lesion · Kidney Transplant Rejection
Next primary completion
23 December 2026 · estimated
Open drug

Lunsekimig

Canonical investigational asset

6
Active trials
2
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 23
  • Phase 33
  • Phase 40
  • Phase not recorded0
Studied condition
Asthma · Chronic Obstructive Pulmonary Disease · Chronic Rhinosinusitis With Nasal Polyps
Next primary completion
21 June 2027 · estimated
Open drug

137 of 184 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

6 selected programmes · accepted investigational links cover 137 of 184 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

Sanofi trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population
VYF Vaccine

NCT07103148

Phase 3 · Recruiting

Trial source and qualifications

A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

1 candidate observations · 1 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

Up to three verified eligible observations in the bounded history window.

  • pc date moved · Recorded 2026-10-14 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

Start: 11 Jul 2025 · actual
Primary completion: 28 Nov 2026 · estimated
Study completion: 04 Mar 2030 · estimated

2021202220232024202520262027202820292030
Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan
Rilzabrutinib

NCT07216079

Phase 3 · Active, not recruiting

Trial source and qualifications

Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

1 inspected observations omitted. At most three verified observations are shown, not full history.

    Start: 15 Oct 2025 · actual
    Primary completion: 30 Nov 2026 · estimated
    Study completion: 30 Nov 2026 · estimated

    2021202220232024202520262027202820292030
    Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents
    PCV21

    NCT06838000

    Phase 3 · Active, not recruiting

    Trial source and qualifications

    Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

    2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    2 inspected observations omitted. At most three verified observations are shown, not full history.

      Start: 28 Feb 2025 · actual
      Primary completion: 01 Dec 2026 · estimated
      Study completion: 01 Dec 2026 · estimated

      2021202220232024202520262027202820292030
      Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older
      Pandemic flu H5 HA mRNA SD2 vaccine

      NCT06907511

      Phase 2 · Active, not recruiting

      Trial source and qualifications

      Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

      2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      2 inspected observations omitted. At most three verified observations are shown, not full history.

        Start: 17 Apr 2025 · actual
        Primary completion: 01 Dec 2026 · estimated
        Study completion: 01 Dec 2026 · estimated

        2021202220232024202520262027202820292030
        CHROMA CD
        Brivekimig

        NCT06958536

        Phase 2 · Recruiting

        Trial source and qualifications

        A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

        1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        1 inspected observations omitted. At most three verified observations are shown, not full history.

          Start: 03 Jun 2025 · actual
          Primary completion: 17 Dec 2026 · estimated
          Study completion: 17 Oct 2029 · estimated

          2021202220232024202520262027202820292030
          COLOR UC
          Brivekimig

          NCT06975722

          Phase 2 · Active, not recruiting

          Trial source and qualifications

          A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis

          Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

          3 candidate observations · 2 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

          ClinicalTrials.gov source

          1 inspected observations omitted. At most three verified observations are shown, not full history.

          • status flip · Recorded 2026-10-03 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
          • enrollment change · Recorded 2026-10-09 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

          Start: 07 Jul 2025 · actual
          Primary completion: 17 Dec 2026 · estimated
          Study completion: 17 Oct 2029 · estimated

          2021202220232024202520262027202820292030

          Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

          6 selected of 84 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 21 actual primary completions, 0 untyped primary completions, 1 past estimates, 6 outside the horizon, 0 contradictory dates.

          04 / Therapeutic focus

          Where the activity is

          25

          active trials in Immunology & Inflammation

          Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

          Active trials by primary therapeutic area

          • Immunology & Inflammation25 trials
          • Infectious Disease23 trials
          • Dermatology21 trials
          • Oncology12 trials
          • Respiratory12 trials
          • Metabolic/Endocrine/Nutrition11 trials
          • Neurology10 trials
          • Haematology9 trials
          • ENT & Hearing5 trials
          • Renal & Urology2 trials
          • Cardiovascular1 trials
          • Gastroenterology & Hepatology1 trials
          • Ophthalmology1 trials
          • Pain & Musculoskeletal1 trials
          • Unmapped47 trials
          • Healthy volunteers3 trials

          Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

          06 / Related companies

          All companies
          A

          AbbVie

          Shared indexed programme context · 1 selected asset

          R

          Regeneron

          Shared indexed programme context · 1 selected asset

          Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

          Sources, scope and methodology

          ClinicalTrials.gov lead-sponsor scope

          Enumerated controlled company group covers 2,381 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: Sanofi · Provention Bio, a Sanofi Company · Synthorx, Inc, a Sanofi company. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion.

          ClinicalTrials.gov

          Attribution coverage

          2,384 distinct registry candidates produced 2,381 accepted studies. 3 mapped to other owners, 0 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 35 unverified, 5 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

          Indexed enrichment

          2,222 scoped records have indexed enrichment and 159 do not. Missing enrichment does not remove a trial from cohort counts.

          Scope observation

          The successful attribution check completed at 2026-11-01T02:10:36.762Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot 09835a3c92b06d82386e95c3e7645c2de22f28b7118a31191991c1d7df9e990f.

          Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

          Dated canonical-attribution snapshot: 2,381 mapped lead-sponsored clinical studies across all statuses. 2,222 have indexed enrichment, 159 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

          Keep following
          what matters.

          Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

          Build your watch

          Choose what to track in the watch builder.